Company intelligence / Profile preview
Denteric
Melbourne, Victoria (VIC), Australiadenteric.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Denteric develops precision immunotherapies and vaccines targeting the major virulence factors of Porphyromonas gingivalis for the treatment and prevention of severe periodontal disease. Their lead product aims to neutralize circulating toxins produced by Pg. The company’s programs are advancing through preclinical and early clinical development stages. No published late-stage or commercial results yet.
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccinesPrecision immunotherapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Denteric.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Denteric.